Kiora reports KIO-300 suppresses seizure activity in preclinical epilepsy model

KIORA PHARMACEUTICALS INC

KIO-300 significantly reduced epileptiform event frequency in hippocampal CA1 slices (p<0.0001).
Suppression persisted through treatment and washout; no impairment of normal electrical transmission.
Data presented at Epilepsy Foundation Pipeline Conference, June 18-19, 2026 in Leesburg, VA.
KIO-300 is the active ingredient of KIO-301, currently in Phase 2 for Retinitis Pigmentosa.
CEO cites broad therapeutic potential beyond ophthalmology; full rights retained outside eye.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.